Quantitative Assessment of Myocardial Perfusion with Magnetic Resonance Using an Intravascular Contrast Agent

• Conditions: Ischemic cardiomyopathy, with inducible ischemia and clinical indication to cardiac revascularization; MedDRA version: 9.1Level: LLTClassification code 10055217Term: Ischemic cardiomyopathy

• Registration Number: EUCTR2008-004895-39-GB
• Lead Sponsor: King's College London

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-10-31
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Patients referred for MR adenosine stress perfusion, with or without known coronary artery disease, with or without prior myocardial revascularization
The subject is =18 years of age
The subject is conscious and able to comply with the study procedures
Written informed consent has been obtained

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Contraindications for MRI
Contraindications to Gadolinium based contrast agents (known allergies or a contra indication to Gd
chelates or renal insufficiency)
Contraindications to Adenosine stress
• Myocardial infarction <3 days
• Unstable angina pectoris
• Severe arterial hypertension
• Asthma or severe obstructive pulmonary disease requiring treatment (chronic obstructive pulmonary disease COPD)
• Sick sinus syndrome or a symptomatic bradycardia, AV block >IIa, trifascicular block
• Allergy against vasodilator
• Allergy against Gadolinium based contrast agents or renal insufficiency
• Other contraindications for adenosine or dipyridamole administration
Pregnancy
Heart failure (NYHA IV)
The subject’s ECG shows prolonged QT interval
Severe arterial hypotension (< 90 mmHg systolic)
Claustrophobia

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified